Breaking Mining Stock News: New Destiny Mining (TSXV: $NED.V) Treasure Mountain Silver - Fully Permitted - Drilling & Trenching 2024 Exploration Program Underway Now; @NEDminingcorp

Breaking Mining Stock News: New Destiny Mining (TSXV: $NED.V) Treasure Mountain Silver - Fully Permitted - Drilling & Trenching 2024 Exploration Program Underway Now; @NEDminingcorp

 

VANCOUVER, British Columbia - June 28, 2024 (Investorideas.com Newswire) New Destiny Mining Corp. (TSXV: NED), (the "Company" or "NED) announces it is preparing to start the 2024 exploration program at its Treasure Mountain project, near Hope, BC.

 

 

 

Map showing Treasure Mountain property and targets for 2024.

"We are excited to commence our 2024 exploration program at the Treasure Mountain project. With the recent repair of the access road and the promising results from our previous surveys, we are optimistic about uncovering significant mineral deposits. This year's focus on the Railroad, David, and Jim Kelly occurrences, along with our efforts at the Superior, Well, and Rio Grande targets, underscores our commitment to advancing this project and creating value for our shareholders," states Barry Brown, Director of New Destiny Mining Corp.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of New Destiny Mining Corp.

 

Read this news featuring NED in full at https://www.investorideas.com/news/2024/06281NED-Treasure-Mountain-Silver-Fully-Permitted.asp

 

About Treasure Mountain Property

The Treasure Mountain property covers 10,819 hectares and is situated 38 km west of the Copper Mountain mine at Princeton in southern BC. Targets on the property include critical minerals in porphyry copper-moly deposits, and gold-quartz vein and polymetallic silver-rich vein deposits.

 

The property surrounds the former Treasure Mountain or Huldra silver mine and is fully permitted for exploration drilling and trenching. Exploration was curtailed due to a wash-out of the access road caused by the 2021 BC atmospheric river event, but the road has now been repaired. An airborne LIDAR survey was flown over the entire property to provide support for field exploration. An airborne magnetic survey is being considered this year to locate delineate porphyry-related source intrusions and outline magnetic anomalies related to mineralization.

 

About Treasure Mountain Exploration Program

The 2024 program will focus on the Railroad, David and Jim Kelly occurrences, with secondary attention directed to the Superior, Well and Rio Grande occurrences.

• Railroad is copper-silver mineralized zone hosted in quartz sericite schist exposed in historic adits. The occurrence is spatially related to a regional magnetic survey anomaly that is interpreted to be a concealed porphyry intrusion. In 2019, a 1.7 metre wide sample across the zone returned values of 1.06% copper and 264 grams per tonne silver. The weighted average grades for consecutive mineralized samples over a 4.2 metre width are 0.64% copper and 116.0 ppm silver. Plans are to drill test the zone and to explore for a northern extension using soil geochemistry and ground geophysics.

 

Hand sample showing chalcopyrite-pyrite mineralization at the Railroad occurrence.

 

Photo showing samples being collected over the alteration zone at Railroad.

• The David prospect was explored historically for porphyry-style copper mineralization. Mineralization consists of disseminated and fracture-filling pyrite, chalcopyrite and pyrrhotite, hosted by a chloritized diorite to hornblendite. Elevated nickel values are reported in association with the Main zone. In 1966, surface sampling of the Main zone yielded up to 0.20 per cent copper, 2.4 grams per tonne silver, and 0.31 per cent nickel over 29.26 metres. Diamond drilling in 1966 yielded intercepts of up to 0.56 per cent copper over 6.0 metres, 0.25 per cent copper over 9.0 metres in drill hole 3, and 0.12 per cent copper over 18 metres in drill hole 1, all from the Northwest zone. Plans for 2024 are to re-locate and sample the exposed showings and evaluate the potential for porphyry copper and nickel-copper sulphide mineralization.
• Jim Kelly Creek is a gold vein target. A 2018 grab sample returned a result of 11.3 grams per tonne gold. Plans are to expose the vein by trenching and then test it by drilling. Geochemical surveys are also being planned.
• Superior is a porphyry copper-molybdenum target. Copper-gold mineralization was identified in multiple quartz veinlets in 2019 trenches. Rock geochemical values for gold ranged up to 1.96 ppm, copper up to 250 ppm, and molybdenum up to 354 ppm. A grab sample of selected mineralized quartz contained 3.99 ppm gold, 96.8 ppm silver, 3560 ppm copper and 45.1 ppm molybdenum.
  
  Superior was tested in 2019 by four short diamond drill holes that penetrated less than 30 meters depth. Quartz veinlets mineralized with pyrite and chalcopyrite were intersected. Analytical results showed elevated copper and molybdenum values, with copper ranging up to 833 ppm and molybdenum ranging up to 88.3 ppm. The source intrusion related to the copper-gold-molybdenum mineralization has yet to be identified.

 

• The Well porphyry Cu-Mo target in the southeastern corner of the property consists of pyrite, chalcopyrite and molybdenite in quartz veins hosted within granodiorite of the Eagle Plutonic Complex. Mineralization is spatially associated with late stage differentiates, including pegmatite, aplite, microgranite and monzonite bodies. Previous surface samples yielded up to 3 wt.% Mo and average 0.5 wt.%. Historic samples from the Wel 11-12 and Wel 15-16 yielded 0.48 to 0.89 wt.% Cu, 5.2 to 36 g/t Ag, and 0.075 to 0.46 g/t Au. For 2024, Verification sampling will be done, and possibly trenching to expose and extend the known mineral occurrences.
• The Rio Grande is a silver-rich polymetallic vein target with similarities to the nearby former Huldra silver mine. 2018 rock grab sample results ranged up to 122 grams per tonne silver, 0.4 % copper, 1.45% zinc and 0.24 grams per tonne gold (Assessment Report 37650). Plans are to collect representative channel samples and design follow-up trenching and drilling.

 

Readers are cautioned that historical records referred to in this News Release have been examined but not verified by a Qualified Person. Further work is required to verify that historical records referred to in this News Release are accurate.

 

Dr. Mathew Ball, P.Geo., a Qualified Person as defined by NI 43-101 and consultant to the Company, approved the technical information contained in this News Release.

 

ON BEHALF OF THE BOARD OF DIRECTORS

"Al Beaton"
Director 604-488-3900

 

Lubica Parilakova

ir@NewDestinyMining.com

Forward-Looking Information

This news release includes certain statements that constitute "forward-looking information" within the meaning of applicable securities law, including without limitation, the Company's information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the completion of the proposed transactions. Forward-looking statements address future events and conditions and are necessarily based upon a number of estimates and assumptions. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved), and variations of such words, and similar expressions are not statements of historical fact and may be forward-looking statements. Forward-looking statement are necessarily based upon several factors that, if untrue, could cause the actual results, performances or achievements of the Company to be materially different from future results, performances or achievements express or implied by such statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of gold and other metals, anticipated costs and the ability to achieve goals, and the Company will be able to obtain required licenses and permits. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks including that resource exploration and development is a speculative business; that environmental laws and regulations may become more onerous; that the Company may not be able to raise additional funds when necessary; fluctuating prices of metals; the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; operating hazards and risks; and competition. There can be no assurance that economic resources will be discovered or developed. Accordingly, actual results may differ materially from those currently anticipated in such statements. Factors that could cause actual results to differ materially from those in forward looking statements include continued availability of capital and financing and general economic, market or business conditions, the loss of key directors, employees, advisors or consultants, equipment failures, litigation, competition, fees charged by service providers and failure of counterparties to perform their contractual obligations. Investors are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. The forward-looking statements included in this news release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation.

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

 

Disclaimer/Disclosure: New Destiny Mining Corp. (NED.V) is a paid featured mining stock on Investor Ideas. More info:Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

 

Get more mining stock investor ideas- news, articles, and podcasts and stock directories

 

 

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update; Conference Call to be Held Today at 4:30 p.m. ET

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update; Conference Call to be Held Today at 4:30 p.m. ET

 

SAN DIEGO, CA, June 27, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments.

 

Company Updates

Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids. These qualities of the Hemopurifier have potential applications in oncology, where cancer associated exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. Aethlon is also investigating the use of the Hemopurifier in the organ transplant setting, initially focusing on the potential removal of viruses and exosomes with harmful cargo from recovered kidneys.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Aethlon Medical Inc.

 

Read this news, featuring AEMD in full at: https://www.investorideas.com/news/2024/06281AEMD-Fiscal-Results-Corporate-Update.asp

 

As announced on June 18, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for three years, until June 13, 2027. The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia.

 

Currently, only approximately 30% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples.

 

"During the fourth quarter and subsequent period, we have continued to make significant progress advancing towards our planned, safety, feasibility and dose finding oncology trials in Australia and India, punctuated by the recent approval from the Human Research Ethics Committee at Central Adelaide Local Health Network," stated James Frakes, Interim Chief Executive Officer and Chief Financial Officer of Aethlon Medical. "Upon submission to the Therapeutic Goods Administration, the national health regulatory agency of Australia, obtaining approval from the CALHN Research Governance Committee, and conducting a site initiation visit, we expect that we will be able to enroll and treat the first patient either in the September quarter or in the December quarter.

"It is also worth noting that in April 2024, the U.S. Food and Drug Administration (FDA) approved our internal manufacturing facility."

 

Mr. Frakes continued, "We anticipate several upcoming, potential value-creating milestones, including submission to the Ethics Committees at two additional sites in Australia and one in India, with the expectation of possibly receiving approval from one or more of those three hospitals in the September quarter of 2024, after which, we expect to be able to enroll patients at those additional sites by the end of 2024."

 

As a reminder, the primary endpoint of the approximate 18-patient, safety, feasibility and dose-finding trial, is safety. The trial will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the PD-1 antibody therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2 or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of subsequent efficacy and safety trials, including a Premarket Approval (PMA) study required by the FDA and other regulatory agencies.

 

The company is also maintaining a position in the use of its Hemopurifier as a treatment against life-threatening viral infections through its COVID-19 trial in India. There are two participating sites for this trial -- the Medanta Medicity Hospital and Maulana Azad Medical College (MAMC). One patient has been treated thus far. However, the company has been informed by its contract research organization that a new COVID-19 subvariant was recently detected in India. The COVID-19 trial in India remains open in the event that there are COVID-19 admissions to the intensive care units at the two participating sites.

 

The company has also received multiple inquiries regarding the current, multi-state outbreak of H5N1 Avian Influenza (H5N1 HPAI) virus in dairy cattle. While the Hemopurifier has demonstrated the ability to capture prior iterations of the H5N1 bird flu virus in invitro experiments, the company has not tested the Hemopurifier against the current strain nor have there been many cases of the current strain infecting humans. The company will continue to monitor the situation and provide any potential updates, as needed.

 

Financial Results for the Fiscal Year Ended March 31, 2024

As of March 31, 2024, Aethlon Medical had a cash balance of approximately $5.4 million and as of June 25, 2024, had a cash balance of approximately $9.1 million.

 

Consolidated operating expenses for the fiscal year ended March 31, 2024 were approximately $12.6 million, compared to approximately $12.5 million for the fiscal year ended March 31, 2023, an increase of approximately $164,000. This increase in the fiscal year ended March 31, 2024 was due to an increase in payroll and related expenses of approximately $763,000, partially offset by decreases in general and administrative expenses of approximately $578,000 and in professional fees of approximately $21,000.

 

The approximate $763,000 increase in payroll and related expenses was primarily due to separation expenses for the company's former chief executive officer of $862,000 and an increase of $127,000 associated with an increase in average headcount, partially offset by a decrease in stock-based compensation of $226,000.

 

The approximate $578,000 decrease in general and administrative expenses was primarily driven by the following: a decrease of $819,000 in clinical trial expenses related to the closed U.S. COVID-19 clinical trial, a decrease of $280,000 in subcontract expense related to contracts and grants with the National Institutes of Health, a $99,000 decrease in rent expense associated with a mobile clean room leased in the prior year, a decrease of $30,000 in travel related expenses associated with a former remote employee and a decrease of $22,000 in expenses related to various other general office operating expenses. These decreases were partially offset by an increase of $405,000 in manufacturing and research and development supplies related to the manufacturing of the company's Hemopurifier device and various research and development activities. Other increases included $118,000 in depreciation expense and amortization expense related to leasehold improvements to manufacturing space, a $70,000 increase in insurance expenses to include medical, D&O and liability, and an increase of $82,000 primarily related to the company's manufacturing facility, encompassing equipment maintenance, utilities, and outside services.

 

The approximate $21,000 decrease in professional fees was primarily due to a decrease in outside scientific, product research and regulatory services of $303,000, a decrease of $60,000 in recruiting fees and a $33,000 decrease in legal fees. These decreases were partially offset by increases in investor relations of $151,000, accounting fees of $137,000, board of director fees of $34,000 and outside operational and administration expenses of $53,000.

 

As a result of the factors noted above, the company's net loss increased to $12.2 million for the fiscal year ended March 31, 2024, from $12.0 million for the fiscal year ended March 31, 2023.

 

The consolidated balance sheet for March 31, 2024, and the consolidated statements of operations for the fiscal years ended March 31, 2024 and 2023 follow at the end of this release.

 

Conference Call

Management will host a conference call today, Thursday, June 27, 2024, at 4:30 p.m. ET to review the company's financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

 

Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10190237/fce977aef1. Please note that registered participants will receive their dial-in number upon registration.

 

Interested parties without internet access or who are unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741

PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

 

All callers should ask for the Aethlon Medical, Inc. conference call.

 

A replay of the call will be available approximately one hour after the end of the call through July 27, 2024. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 6876352.

 

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

Additional information can be found at www.AethlonMedical.com.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital and to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to submit applications to and obtain approval from the additional Ethics Committees in Australia and India, including on the timing expected by the Company; the Company's ability to initiate its planned oncology clinical trials in Australia and India, including on the timing expected by the Company; the Company's ability to manage and successfully complete its clinical trials, if initiated; the potential impact of Hemopurifier on the H5N1 Avian Influenza (H5N1 HPAI) virus in dairy cattle; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:

Jim Frakes

Interim Chief Executive Officer and Chief Financial Officer

Aethlon Medical, Inc.

Jfrakes@aethlonmedical.com

 

Investor Contact:

Susan Noonan

S.A. Noonan Communications, LLC

susan@sanoonan.com

917-513-5303

 

SOURCE Aethlon Medical, Inc.

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Breaking Cleantech Stock News: dynaCERT (TSX: $DYA.TO) (OTCQX: $DYFSF) Furthers its Market Penetration in Oil & Gas Markets; @dynaCERT

Breaking Cleantech Stock News: dynaCERT (TSX: $DYA.TO) (OTCQX: $DYFSF) Furthers its Market Penetration in Oil & Gas Markets; @dynaCERT

 

TORONTO, June 27, 2024 - (Investorideas.com Newswire) dynaCERT Inc. (TSX: DYA) (OTCQX: DYFSF) (FRA: DMJ) ("dynaCERT" or the "Company") is pleased to announce a follow-up purchase order of eighty-four (84) HG1 HydraGEN™ Units from its dealer, Simply Green Distributors Inc. ("Simply Green") of Alberta, destined for the leading oil and gas drilling contractor in Canada (the "Contractor").

 

This new purchase order is in addition to a recent purchase order of eighteen (18) HG1 HydraGEN™ Technology Units from Simply Green for use on the Contractor’s drilling rigs operating in Canada. This purchase order was received after an extensive and successful due diligence trial of HydraGEN™ Technology for a total deployment of 103 HydraGEN™ Units of dynaCERT.

 

In this application, dynaCERT’s HydraGEN™ Technology is designed to enhance the fuel economy of engines powering drilling rigs, reducing diesel usage and thus improving emissions performance.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of dynaCERT Inc.

 

Read this news, featuring DYA in full at https://www.investorideas.com/news/2024/06281DYA-Oil-Gas-Markets.asp

 

James Pearce, President & CEO of Simply Green stated, "With its impressive emissions reduction capabilities, dynaCERT’s HydraGEN™ Technology is quickly gaining popularity in the Oil & Gas industry as a cost-effective and environmentally friendly solution to reducing carbon footprints. As dynaCERT’s Western Canadian dealer, we have worked very thoroughly with the Contractor and dynaCERT personnel in the last year and thank them for the constructive outcome of everyone’s efforts."

 

Jim Payne, Chairman and CEO of dynaCERT, stated, "dynaCERT congratulates and thanks the Contractor and Simply Green for their commitment to reducing GHG emissions with our HydraGEN™ Technology. It is so important to dynaCERT to see such a strong pledge in our own country, Canada, after twenty years of R&D and constant improvements of our HydraGEN™ Technology. All our global key dealers, such as Simply Green, understand the need to reduce global warming, and all our outstanding clients operating worldwide support our commitments to the resources industry."

 

About Simply Green Distributors Inc.

Simply Green is proud to be one of the leading experts and distributors in hydrogen and continues to push for the development of new, innovative hydrogen products. Simply Green believes that investing in hydrogen is not just a smart financial decision, but also a moral imperative to help protect our planet and ensure the well-being of future generations. See: https://www.simplygreendistributors.ca/

 

About dynaCERT Inc.

dynaCERT Inc. manufactures and distributes Carbon Emission Reduction Technology along with its proprietary HydraLytica™ Telematics, a means of monitoring fuel consumption and calculating GHG emissions savings designed for the tracking of possible future Carbon Credits for use with internal combustion engines. As part of the growing global hydrogen economy, our patented technology creates hydrogen and oxygen on-demand through a unique electrolysis system and supplies these gases through the air intake to enhance combustion, which has shown to lower carbon emissions and improve fuel efficiency. Our technology is designed for use with many types and sizes of diesel engines used in on-road vehicles, reefer trailers, off-road construction, power generation, mining and forestry equipment. Website: www.dynacert.com

 

READER ADVISORY

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, information relating to Simply Green Distributors Inc. and the Contractor cannot be independently verified. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance of achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; the uncertainty of the emerging hydrogen economy; including the hydrogen economy moving at a pace not anticipated; our ability to secure and maintain strategic relationships and distribution agreements; and the other risk factors disclosed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

 

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of the release.

 

On Behalf of the Board of dynaCERT Inc.

Murray James Payne, CEO

Contacts

For more information, please contact:

dynaCERT Inc.

Jim Payne, Chairman & CEO

#101 – 501 Alliance Avenue

Toronto, Ontario M6N 2J1

+1 (416) 766-9691 x 2

jpayne@dynaCERT.com

 

dynaCERT Inc.

Nancy Massicotte

Investor Relations

+1 (416) 766-9691 x 1

nmassicotte@dynaCERT.com

 

dynaCERT Inc. (TSX:DYA.TO) (DYFSF) is a featured Renewable Energy / Fuel Cell stock on Investorideas.com

 

Visit profile page

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. contact management and IR of each company directly regarding specific questions. Disclosure. DYA is a monthly featured cleantech stock on Investorideas.com effective March 1, 2024 for 6 months. (equivalent of 3500 month in stock) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Get more Renewable Energy Stock news, articles, podcasts and Stock Directories

 

Canadian Nickel Shining Through-(TSXV: $ENVI.V) (TSXV: $FPX.V) (TSXV: $FLYN.V) (TSXV: $ZBNI.V)

Canadian Nickel Shining Through-(TSXV: $ENVI.V) (TSXV: $FPX.V) (TSXV: $FLYN.V) (TSXV: $ZBNI.V)

 

Battery Metal Stocks to Watch-(ASX: $FBM.AX) (CSE: $VR.CN) (TSXV: $SCLT.V) (ASX: $AUZ.AX)

 

 

 

 

June 28, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Mining sector.  

 

The newest mining companies are involved in nickel mining along with other battery metals, including lithium and cobalt.

 

Read this in full at https://www.investorideas.com/news/2024/main/06281Stocks.asp

 

Investor Ideas is always on the hunt for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector. 

 

New Stocks Added to the Mining Directories:

EV Nickel Inc (TSXV:ENVI) mission is to accelerate the transition to clean energy. It is a Canadian nickel exploration company, focused on the Shaw Dome Project, south of Timmins, Ontario. EVNi has over 30,000 hectares to explore across the Shaw Dome and has identified >100 km of additional favourable strike length. The Shaw Dome includes the High-Grade W4 Deposit- with a combined Resource of 2.0M tonnes @ 0.98% Ni for 43.3M lbs of Class 1 Nickel consisting of Measured and Indicated Resources of 1.45M tonnes @ 0.98% Ni and Inferred Resources of 0.6M tonnes @ 0.98% Ni and the Large-Scale CarLang Area with more than 10km of mineralization and where the first 20% contains the A Zone- with a combined Resource of 1.1B tonnes @ 0.24% Ni for 5.3B lbs of Class 1 Nickel consisting of Indicated Resource of 0.5B tonnes @ 0.25% Ni and an Inferred Resource of 0.5B tonnes @ 0.23% Ni. EVNi owns the trademark for Clean Nickel and plans to grow and advance a Clean Nickel™ business, targeting the growing demand from the electric vehicle battery sector. The Company is focused on a 2-track strategy: Track 1- to produce High-Grade Clean Nickel™ (starting with W4) and Track 2- an integrated Carbon Capture & Storage project with Large-Scale Clean Nickel™ production (starting with CarLang).

 

FPX Nickel Corp (TSX-V:FPX) is focused on the exploration and development of the Decar Nickel District, located in central British Columbia, and other occurrences of the same unique style of naturally occurring nickel-iron alloy mineralization known as awaruite.

 

Flying Nickel Mining Corp (TSX-V:FLYN) is a nickel sulphide exploration-stage mining company. The Company is advancing its 100% owned Minago nickel project in the Thompson nickel belt in Manitoba, Canada.

 

Zeb Nickel (TSX-V:ZBNI) is focused on exploring for and developing world-class mineral deposits, with a focus on metals that are critical in the production of rechargeable batteries, such as nickel, graphite, lithium, cobalt, manganese, copper and aluminum. The Company is currently focused on developing its flagship Zeb Nickel Project, located in Limpopo, South Africa. The Zeb Nickel Project is a developing Class 1 nickel sulfide project strategically located in the Bushveld Complex in South Africa.

 

Future Battery Minerals Ltd (ASX:FBM) is a future-facing minerals exploration and development company focused on rapidly advancing our two world-class lithium discoveries.

Our Kangaroo Hills Lithium Project (KHLP) is a recent and exciting hard rock lithium discovery located in the Goldfields of Western Australia, approximately 17km south of the major township of Coolgardie. Immediately north and contiguous to KHLP is the recently acquired Miriam Project, where a large historic lithium soil anomaly extends from an outcropping spodumene-rich pegmatite, providing a significant opportunity for future exploration success. Our Nevada Lithium Project (NLP) comprises over 90km2 of tenure considered highly prospectivefor sedimentary-hosted lithium deposits. A large-scale, high-grade maiden Mineral Resource Estimate was recently delivered for the Lone Mountain deposit within NLP less than 12 months from discovery.

 

Victory Battery Metals Corp (CSE:VR) is a publicly traded diversified investment corporation with mineral interests in North America. The company is also actively seeking other exploration opportunities.

 

Searchlight Resources Inc. (TSX:SCLT.V) is a Canadian mineral exploration and development company focused on Saskatchewan, Canada, which has been ranked as the top location for mining investment in Canada by the Fraser Institute. The Company's exploration model of Project Generation coupled with Targeted Exploration, focuses on battery minerals and gold throughout the province.

 

Australian Mines Ltd. (ASX:AUZ) is positioned to be one of the world's most cost-competitive producers and suppliers of technology metal materials to the high-growth Electric Vehicle and Energy Storage industries. Australian Mines 100% owned, low cost, Sconi Project in Queensland is expected to deliver sustainable nickel and cobalt from the first mineral resources company to be a Carbon Neutral certified organisation by the Australian Government, Australian Mines. Australian Mines also has a number of other promising assets and development strategies and process options at Sconi, providing flexibility and diversity through the project's lifespan.

 

 

For the avid Mining Stock Investors – Check out our free comprehensive directory of Mining Stocks Mining Stocks Directory

 

 

 

Stay up to date on current mining sector news at https://www.investorideas.com/Gold_Stocks/ and Get News Alerts on Mining Stocks

 

 

Check out the Exploring Mining podcast by Investor Ideas for the latest mining stock news and insightful interviews with top industry experts. We're proud to have been recognized as number 1 in the top 30 Mining Podcasts to listen to in 2024 by Feedspot based on a review of thousands of podcasts on the web and ranked by traffic, social media followers & freshness. Host Cali Van Zant interviews CEO's and analysts to give you insight into the sector. Stay ahead of the game with Exploring Mining.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X)  https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411